APA (7th ed.) Citation

NU, L., H, G., JT, Y., IA, M., CI, F., TJ, H., . . . AD, V. d. A. (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(24), 2623. https://doi.org/10.1200/JCO.2014.60.0353

Chicago Style (17th ed.) Citation

NU, Lin, et al. "Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 24 (2015): 2623. https://doi.org/10.1200/JCO.2014.60.0353.

MLA (9th ed.) Citation

NU, Lin, et al. "Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 33, no. 24, 2015, p. 2623, https://doi.org/10.1200/JCO.2014.60.0353.